drugset / Trial / NCT04276909
Feasibility Study of LUM Imaging System for Pancreatic Cancer
Withdrawn
Lumicell, Inc.
NaSingle-groupOpen-labelOther
Summary
This single-site, non-randomized, open-label study to assess the initial safety and efficacy of the LUM Imaging System for detection of primary pancreatic cancer and peritoneal invasion from primary pancreatic cancer during surgery. In this feasibility study, the tumor detection algorithm will be developed for this indication.
Timeline
- Start
- 2026-01
- Primary completion
- 2026-01
- Completion
- 2026-01
Outcome
Outcome not reported
Stopped: “Study not initiated.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PEGULICIANINE ACETATE | Diagnostic / imaging agent | 1 mg/kg | Intravenous |